Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Exon20 Insertion Mutations”

60 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 60 results

Large-scale testing (Phase 3)Looking for participantsNCT07182682
What this trial is testing

Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 360
Early research (Phase 1)Not Yet RecruitingNCT05940116
What this trial is testing

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerSolid Tumor
Hansoh BioMedical R&D Company 322
Testing effectiveness (Phase 2)Study completedNCT03727724
What this trial is testing

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 37
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Early research (Phase 1)WithdrawnNCT04958967
What this trial is testing

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc.
Not applicableApproved For MarketingNCT04599712
What this trial is testing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Not applicableApproved For MarketingNCT04535557
What this trial is testing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Millennium Pharmaceuticals, Inc.
Early research (Phase 1)Ended earlyNCT05241873
What this trial is testing

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Who this might be right for
Lung Neoplasm MalignantCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+17 more
Blueprint Medicines Corporation 103
Large-scale testing (Phase 3)Not Yet RecruitingNCT05767892
What this trial is testing

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Suzhou Puhe Pharmaceutical Technology Co., LTD 350
Large-scale testing (Phase 3)Enrolling By InvitationNCT06281964
What this trial is testing

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 327
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Testing effectiveness (Phase 2)Looking for participantsNCT06043817
What this trial is testing

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Who this might be right for
Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament 345
Early research (Phase 1)Study completedNCT04858958
What this trial is testing

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 90
Testing effectiveness (Phase 2)Looking for participantsNCT06706713
What this trial is testing

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc 200
Testing effectiveness (Phase 2)Ended earlyNCT03805841
What this trial is testing

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Who this might be right for
NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more
Rain Oncology Inc 41
Testing effectiveness (Phase 2)Looking for participantsNCT06864624
What this trial is testing

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Who this might be right for
NSCLC
Tang-Du Hospital 27
Next Page